Cyclophosphamide, bortezomib and dexamethasone (CyBorD) is a highly active three-drug induction regimen for untreated transplant-eligible multiple myeloma patients. Although CyBorD has been evaluated only in the phase 2 setting in a limited number of patients, its high efficacy and ease of administration have led to its widespread use. Given that clinical trial efficacy can overestimate real-life effectiveness, we reviewed our institutional experience with 109 newly diagnosed patients who were treated with CyBorD in a non-clinical trial setting. After a median of four cycles, overall response rate (ORR) and very good partial response rate or better (⩾ VGPR) were 95 and 66%, respectively, comparable to phase 2 studies of CyBorD and other three/four-drug induction regimens. All patients subsequently underwent successful stem cell collection and upgraded responses to ORR 98% and ⩾ VGPR 79% post transplant. At a median follow-up of 19.8 months after diagnosis, the 2-year OS probability was 95.3% (95%CI: 89-98). The presence of concurrent plasmacytoma at diagnosis was the only prognostic factor predicting poorer survival (HR = 5.56; 95%CI: 0.92-33.74; P = 0.03). CyBorD was well-tolerated, with no severe peripheral neuropathy and minimal hematologic toxicity. Therefore, CyBorD is a convenient, well-tolerated, highly effective induction regimen in preparation for autologous SCT in real-life clinical practice. 
INTRODUCTION
Currently, the standard of care for induction therapy in preparation for autologous SCT (ASCT) involves incorporation of novel agents such as bortezomib and/or immunomodulatory agents (thalidomide or lenalidomide). [1] [2] [3] [4] [5] [6] [7] [8] [9] [10] [11] Two-and three-drug combinations can lead to high overall response rates (ORR) of 61-100% and very good partial responses (VGPR) of 34-67%. [1] [2] [3] [4] [5] [7] [8] [9] [10] [11] [12] [13] No combination, however, has shown clear superiority in terms of progression-free survival (PFS) or overall survival (OS). Hence, in clinical practice, a balance between efficacy, toxicity, ease of administration and cost should be considered when identifying an optimal induction regimen.
CyBorD is a highly active three-drug induction regimen that has been widely adopted for use in preparation for transplant. In the original phase 2 study evaluating CyBorD using biweekly bortezomib 1.3 mg/m 2 (days 1, 4, 8 and 11), weekly cyclophosphamide (Cy) 300 mg/m 2 orally (days 1, 8, 15 and 22) and dexamethasone 40 mg orally (days 1-4, 9-12 and 17-20) on a 28-day cycle, ORR of 88% and ⩾ VGPR rates of 61% were achieved after four cycles (n = 33). 7 In an expanded cohort of the same trial (n = 30), a modified dosing schedule using a higher bortezomib dose-1.5 mg/m 2 given once weekly (days 1, 8, 15, 22) and in combination with a lower dose of dexamethasone (40 mg once weekly for cycles 3 and 4)-attained responses equivalent to the twice-weekly cohort (ORR 93% and ⩾ VGPR 60%) with less toxicity. The incidence of peripheral neuropathy was lower (57 vs 64%), with no grade 3-4 peripheral neuropathy documented, despite the higher total dose of bortezomib used in each cycle (6 vs 5.2 mg/m 2 ). 8 The excellent long-term survival outcome has been recently reported (median PFS was 40 months, 5-year PFS 42%, 5-year OS 70%). 14 Although CyBorD has been evaluated only in phase 2 studies, it has gained widespread popularity as an induction regimen due to its remarkable efficacy, excellent safety profile and ease of administration, and has been adopted for routine use at many institutions, including our own. Given that clinical trial efficacy can overestimate real-life effectiveness due to exclusion of patients with high-risk features, renal impairment and poor performance status, we aimed to evaluate our institutional experience of CyBorD to assess efficacy, tolerability and safety of CyBorD in real-life clinical practice.
MATERIALS AND METHODS Patients
Between April 2007 and April 2012, 109 multiple myeloma patients who received CyBorD induction therapy outside of a clinical trial in preparation for ASCT were reviewed. Patient demographics, disease characteristics, details of induction therapy and ASCT, and survival outcomes were obtained from retrospective review of patient charts and a prospectively maintained transplant database. Approval for this review was obtained from the Princess Margaret Cancer Centre Institutional Review Board in accordance with the Declaration of Helsinki.
Details of CyBorD regimen, stem cell mobilization and ASCT
The CyBorD regimen consisted of bortezomib 1.5 mg/m 2 i.v. on days 1, 8, 15 and 22, Cy 300 mg/m 2 orally on days 1, 8, 15 and 22 and dexamethasone 40 mg orally on days 1-4, 9-12, 17-20 for the first two cycles, then 40 mg weekly for subsequent cycles. CyBorD was given on a 28-day cycle for a target of 4-6 cycles before proceeding to stem cell collection and transplantation. Additional cycles could be given after stem cell collection while awaiting transplant in the event of a delay. All patients received acyclovir for herpes zoster prophylaxis. Stem cell mobilization was conducted as per the institutional protocol using high-dose Cy 2.5 gm/m 2 followed by G-CSF 10 µg/kg/day. High-dose melphalan 200 mg/m 2 was used as the standard conditioning regimen.
Response assessment
Clinical responses were assessed after each cycle during the CyBorD induction period, before stem cell mobilization and at 100 days post transplant. The International Myeloma Working Group Uniform Response Criteria were used to assess treatment response. 15 Complete response (CR) was defined as negative immunofixation on serum and urine with disappearance of any soft tissue plasmacytomas and o5% BM plasma cells. VGPR was defined as serum and urine M-protein detectable by immunofixation but not on electrophoresis or ⩾90% reduction in M-protein with urine M-proteino100 mg/24 h. Partial response (PR) was defined as a 50% reduction in serum M-protein. Progressive disease (PD) was defined as a 25% increase in serum or urine M-protein with a minimum absolute increase of ⩾ 5.0 g/L in serum or ⩾ 200 mg/24 h in urine. Stable disease (SD) was defined as not meeting criteria for VGPR, PR or PD. In this clinical experience, BM biopsies were not routinely performed after induction or post-ASCT, therefore confirmation of CR was not available in the usual circumstance and patients with the absence of monoclonal protein on immunologic studies were classified as having a VGPR or better (⩾ VGPR).
Toxicity
All adverse events during CyBorD treatment were reviewed. Toxicities were graded according to the National Cancer Institute Common Toxicity criteria (NCI-CTC), version 4.0.
Statistical analysis
OS information was available in all patients, and was calculated from time of myeloma diagnosis to date of death or last follow-up. Survival analyses were performed using the Kaplan-Meier method. Univariate analyses of baseline characteristics and response assessments were performed using the Cox proportional hazard model and log rank methods. As most patients were referred after recovery from ASCT back to their initial center of care, data on progression were not collected for this analysis.
RESULTS

Patients
Baseline characteristics of all 109 MM patients who received weekly CyBorD induction in preparation for ASCT are summarized in Table 1 . Fifteen patients had high-risk FISH cytogenetics with del 17p, t(4;14) or t(14;16), including one patient with concurrent del 17p and t(14;16). Nineteen patients (17%) presented with renal impairment (defined as serum creatinine 4177 μmol/L) with a mean serum creatinine of 363 μmol/L (range 177-832). Two patients were receiving regular hemodialysis at the time of first cycle of CyBorD. Five patients had plasma cell leukemia (PCL) at presentation (circulating plasma cells greater than 20%). Not surprisingly, three of the five PCL patients had high risk FISH cytogenetics: one patient with t(14;16) and two patients with del (17p). Plasmacytomas were present in 21 patients (19%). One patient had concurrent light chain amyloidosis involving the liver, spleen, pancreas and lymph nodes.
Efficacy
We were able to assess treatment response after CyBorD induction in 108 patients. One non-secretory myeloma patient could not be evaluated due to missing BM information. After a median of four cycles (range 1-6) of chemotherapy, high-response rates were achieved: ORR 95% and ⩾ VGPR 66%. One hundred and two patients (94%) who completed four cycles of CyBorD achieved an ORR of 95% and ⩾ VGPR of 68% as summarized in Table 2 . Best treatment responses were achieved after a median of four cycles (range [1] [2] [3] [4] [5] [6] . High efficacy was also demonstrated in myeloma patients with high-risk features as summarized in Table 3 . All patients with high risk FISH cytogenetics responded after CyBorD induction. However, patients who presented with concurrent plasmacytomas had the lowest response rates (ORR 90% and ⩾ VGPR 55%) amongst patients with high-risk features. Fourteen patients (74%) with renal impairment at baseline improved their serum creatinine levels to o 177 umol/L after CyBorD induction. Six patients did not complete the four planned cycles of CyBorD: three patients underwent ASCT following response after three cycles of CyBorD, two patients had disease progression after one and three cycles of CyBorD and were switched to second-line treatment, one patient had severe Crohn's disease with bowel obstruction required surgery and discontinued treatment after one cycle. As summarized in Table 4 , eight patients progressed before ASCT, after a median of four cycles (range 1-4 cycles), with (n = 33)
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Abbreviations: n = number of patients; ORR = overall response; VGPR = very good partial response.
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Stem cell mobilization and ASCT All patients underwent stem cell mobilization using Cy and G-CSF, except for one patient with concurrent MM and light chain amyloidosis who received G-CSF alone for mobilization. All patients had successful stem cell collections, requiring a median of one leukapheresis (range 1-4). The median number of CD34+ cells collected was 8 ×10 6 /kg body weight (range 2.3-24.5 × 10 6 / kg). All patients proceeded to auto-SCT, except for three patients (one patient with del 17p progressed and died before ASCT, one patient was deemed ineligible due to severe mitral stenosis and one patient declined). Melphalan 200 mg/m 2 was used for conditioning in 100 patients (94%). Six patients received reduced dose melphalan (140 mg/m 2 ) due to renal impairment. A median of 4.04 × 10 6 /kg CD34+ cells were infused (range 1.48-12.4). Higher-response rates were obtained at 100 days post transplant (ORR 98%; ⩾ VGPR 79%). Toxicity All patients were assessed for toxicity. Grade 3-4 adverse events related to therapy are summarized in Table 5 . The most common grade 3-4 adverse events were infection (10%) and neutropenia (4%). Pneumonia was the most common site of infection (5%). Using routine antiviral prophylaxis, grade 3-4 herpes infections were not common (2.8%). Grade 1-2 peripheral neuropathy occurred in 33 patients (31%), with no severe (grade 3-4) neuropathy noted. Grade 3-4 hematologic adverse events were uncommon with only 4 patients (4%) with grade 3-4 neutropenia and no grade 3-4 thrombocytopenia or anemia. CyBorD was welltolerated even in patients with renal failure (n = 19) with no grade 3-4 hematologic toxicity among these patients. Grade 3-4 nonhematologic adverse events occurred in 4 patients with renal impairment (21%) ( Table 5) . Dose modifications Dose reductions and/or delays of any agents in the regimen were required in 29 patients (27%). The most frequently dose-reduced agent was dexamethasone in 15 patients (14%), mainly due to edema (7%). Eight patients (7%) required dose reduction of bortezomib, mainly due to grade 1-2 neuropathy. Only 4 patients (4%) required Cy dose modification, due to grade 4 neutropenia, severe nausea/fatigue, renal impairment and non-treatment related grade 4 transaminitis, respectively. Grade 4 transaminitis in one patient was attributed to isoniazid administered for latent tuberculosis but Cy was dose-reduced as a precaution; with isoniazid discontinuation, the transaminitis resolved completely.
Among 19 patients with renal impairment, 5 patients (26%) required dose reduction of the agents in CyBorD; dexamethasone in 4 patients (21%) due to grade 1-2 peripheral edema (three patients) and grade 2 myopathy (one patient); Cy in two patients due to severe fatigue and nausea (one patient), empiric reduction for renal impairment due to physician preference (one patient) and bortezomib in one patient due to grade 1 peripheral neuropathy. Abbreviations: del = deletion; EMP = extramedullary plasmacytoma; ISS = international staging system; ORR = overall response rate; PCL = plasma cell leukemia; RI = renal impairment; VPGR = very good partial response. Abbreviations: CNS RT = central nervous system radiotherapy; Cy = etoposide; D-PACE = dexamethasone, cisplatin, doxorubicin; DT-PACE = dexamethasone, thalidomide, cisplatin, doxorubicin; EMP = extramedullary plasmacytoma; F = female; FLC = free light chain; K = kappa; L = lambda; M = male; PCL = plasma cell leukemia; PD = progressive disease; PR = partial response; Pt = patient; Rd = lenalidomide and dexamethasone; RI = renal impairment; RVD = lenalidomide, bortezomib, dexamethasone; SD = stable disease; VGPR = very good partial response.
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Survival outcomes
At a median follow-up of 19.8 months after diagnosis (range 7-67.7), 6 of 109 patients (6%) have died. Causes of death include the following: disease progression (four patients) and pneumonia within 100 days of ASCT (two patients). Survival probabilities at 1, 2 and 5 years were 95.3% (95%CI: 89-98), 95.3% (95%CI: 89-98) and 91.5% (95%CI: 78-96), respectively, as shown in Figure 1 . On univariate analysis, the presence of concurrent plasmacytomas at diagnosis was the poor prognostic factor impacting survival (HR = 5.56; 95%CI: 0.92-33.74; P = 0.03) as demonstrated in Figure 2 .
DISCUSSION
Novel three and even four-drug combinations have become standard as induction treatment for MM patients preparing for high-dose therapy and stem cell rescue. 3, 5, [7] [8] [9] [10] [11] [12] [13] Ideally, an induction regimen should be highly effective, convenient, welltolerated and economical. Given these lofty aspirations, the optimal induction regimen has not yet been identified. CyBorD has gained popularity as an induction regimen given its ease of administration and excellent safety profile; however, efficacy has been extrapolated into real-life practice only from data generated by phase 2 trials. In our evaluation of CyBorD use in a non-trial setting, we were able to confirm the high efficacy of once weekly CyBorD with an ORR 95% and ⩾ VGPR rate of 66%, comparable to results from the original CyBorD phase 2 data published by Reeder et al. (Table 4) , as well as to other three-and four-drug combinations in the literature. [9] [10] [11] [12] [13] 16 Of note, CyBorD outcomes appear comparable to that of VRD (bortezomib, lenalidomide and dexamethasone) and VTD (bortezomib, thalidomide and dexamethasone), two of the most effective induction regimens reported with ORR of 100 and 93-95%; ⩾ VGPR of 67% and 60-62%, respectively. 3,9,10 Comparison of induction response among three-and four-drug regimens is summarized in Table 6 . In the EVOLUTION trial, the four-drug regimen, bortezomib, lenalidomide, Cy and dexamethasone (VDCR), failed to show benefit over other three-drug regimens including a regimen with similar components to CyBorD. Abbreviations: CyBorD = Cy-bortezomib-dexamethasone; CRD = Cylenalidomide-dexamethasone; n = number of patients; PAD = bortezomib-doxorubicin-dexamethasone; VDR = bortezomib-lenalidomide-dexamethasone; VDCR = bortezomib-dexamethasone-Cy-lenalidomide; VTDC = bortezomibthalidomide-dexamethasone-Cy.
CyBorD induction therapy in multiple myeloma N Areethamsirikul et al discontinuations with the three-drug versus four-drug combinations suggest that 'more' is not necessarily better. In our study, CyBorD toxicities were manageable, with few grade 3-4 hematologic adverse events and no compromise in ability to mobilize stem cells. The absence of grade 3-4 peripheral neuropathy is remarkable and compares favorably with rates of this complication associated with other novel agent combinations, specifically 10% with VTD (bortezomib, thalidomide and dexamethasone), 13% with VRCD, and 8% with VTCD (bortezomib, thalidomide, Cy and dexamethasone). 3, 12, 16 CyBorD is convenient and easy to administer with the bortezomib in a once-weekly schedule. Moreover, the current standard of care has moved from an i.v. to a s.c. mode of administration for bortezomib, associated with further reduction of the incidence of peripheral neuropathy with similar efficacy to the i.v. route. 17 In addition, the use of a higher single dose of s.c. bortezomib (with volumes up to 3 ml) is feasible, with limited skin reactions, and eliminates the need to administer at two injection sites in 81% of patients. 18 The s.c. route further enhances the convenience of this regimen.
Without the constraints of clinical trial eligibility, our real-life experience with CyBorD included the treatment of patients with high-risk features, including PCL and severe renal impairment (including dialysis-dependency). All PCL patients in our series responded to CyBorD and those with renal impairment appeared to tolerate the regimen well, with a high rate of renal improvement. No renal dose adjustment is required with bortezomib even in dialysis-dependent patients 19, 20 and Cy requires dose reduction only with severely impaired creatinine clearance of 10 ml/min or less. Therefore, this induction regimen is well-suited for use in newly diagnosed myeloma patients in whom renal impairment is common.
Finally, it is worth commenting that CyBorD is a relatively costeffective regimen. When compared with VRD induction, VCD (a similar regimen of bortezomib, Cy and dexamethasone) led to similar survival outcomes and manageable toxicities, but at a significant cost differential ($29 468 USD less per treatment course for VCD compared with VRD). 21 
CONCLUSION
CyBorD using weekly bortezomib as a three-drug induction regimen before ASCT is highly effective in real-life clinical practice. We demonstrated efficacy similar to the data from phase 2 studies of CyBorD and other novel three/four-drug regimens. CyBorD is well-tolerated with routine administration of a single higher dose given weekly s.c. and represents a convenient and relatively costeffective induction regimen.
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